A pyridazinone or pyridone compound of general formula (I '), or pharmaceutically acceptable salt, hydrate or solvate thereof, ** Formula ** wherein X is CH or N； R 1 is phenyl, optionally substituted with R 11, wherein R 11 is selected from the group consisting of halogen, halo-C 1-3 alkyl, and C 1-6 alkoxy； R2 is H or triazolyl； (i) X3 is O or S, and R3 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, and phenyl, said phenyl being optionally substituted one or more times with R31, each R31 is independently selected from the group consisting of halogen, halo-C 1-3 alkyl and C 1-6 alkoxy； or (ii) X3 is NR3 ', and R3 and R3' together with the nitrogen, to which they are attached, together form a group selected from the group consisting of optionally substituted N-methyl piperazinyl, pyrrolidinyl, 1,2,3-triazolyl , said 1,2,3-triazolyl being optionally substituted with R32, wherein R32 is selected from the group consisting of phenyl, C1-6 alkyl, and -CO2 (C1-3 alkyl)； or R3 'is H or C1-3 alkyl, and R3 is selected from the group consisting of H； C1-6 alkyl； C2-6 alkenyl； C2-6 alkynyl； C3-6 cycloalkyl-C1-6 alkyl； C1-6 cycloalkyl； cyano-C1-6 alkyl； amino C1-6 alkyl； benzyl； pyridyl； saturated 5- or 6-membered heterocyclic ring having 1 to 2 heteroatoms selected from N, O and S, and wherein said N is optionally substituted with C1-6 alkyl； R33R33'N-C1-6 alkylenyl； and phenyl, said phenyl being optionally substituted 1 to 3 times with R34； wherein R33 and R33 'are both C1-3 alkyl, or R33 and R33' together with the nitrogen, to which they are attached, form a saturated 5 or 6 membered heterocyclic ring optionally comprising an additional heteroatom selected from N, O and S； each R34 is independently selected from the group consisting of NR35R35 ', hydroxy and C1-6 alkoxy； or two adjacent R34 together with the carbon atoms, to which they are attached, form a 5 or 6 membered fused heterocyclic ring comprising 1 or 2 heteroatoms each independently selected
